The proof of this concept has been provided by the remarkable antitumour activity of the small BCR (breakpoint cluster region)-ABL (Abelson) TK inhibitor imatinib in chronic myeloid leukaemia (CML) [11]. The gene discussed is TKT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.